The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
Open accessAbstract
In patients with acute leukemia, detection of minimal residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) correlates with risk of relapse. However, the level of MRD that is most likely to preclude cure by HCT is unclear, and the benefit of further chemotherapy to reduce MRD before HCT is unknown. In 122 children with very-high-risk acute lymphoblastic leukemia (ALL; n = 64) or acute myeloid leukemia (AML, n = 58), higher MRD levels at the time of HCT predicted a poorer survival after HCT (P = .0019); MRD was an independent prognostic factor in a multivariate analysis (P = .0035). However, the increase in risk of death associated with a similar increment of MRD was greater in ALL than in AML, suggesting that a pretransplantation reduction of leukemia burden would have a higher impact in ALL. At any given MRD level, survival rates were higher for patients treated in recent protocols: the 5-year overall survival for patients with ALL was 49% if MRD was detectable and 88% if it was not and the corresponding rates for patients with AML were 67% and 80%, respectively. Although MRD before HCT is a strong prognostic factor, its impact has diminished and should not be regarded as a contraindication for HCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Self-citationMalard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Relapsed childhood acute lymphoblastic leukaemia
Bhojwani, D., & Pui, C.-H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70580-6 · Cited by 414
Self-citationCollaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., De Bont, E. S. J. M., De Moerloose, B., Dworzak, M., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 383
Self-citationWalter, R. B., Buckley, S. A., Pagel, J. M., Wood, B. L., Storer, B. E., Sandmaier, B. M., Fang, M., Gyurkocza, B., Delaney, C., Radich, J. P., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506725 · Cited by 360
Metadata
- Authors
- Leung, W., Pui, C.-H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B. M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J. E., Sandlund, J. T., Jeha, S., Inaba, H., Ribeiro, R. C., Handgretinger, R., Laver, J. H., & Campana, D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-07-12
- Volume
- 120
- Issue
- 2
- Pages
- 468-472
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2083006206
- Cited by
- 191
- References
- 1
- FWCI
- 21.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. https://app.cochat.ai/papers/10.1182/blood-2012-02-409813
- The paper
- Leung, W., Pui, C.-H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B. M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J. E., Sandlund, J. T., Jeha, S., Inaba, H., Ribeiro, R. C., Handgretinger, R., Laver, J. H., & Campana, D. (2012). Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. https://doi.org/10.1182/blood-2012-02-409813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.